Mother-to-child transmission of hepatitis B in Far North Queensland, 2013–2023
DOI:
https://doi.org/10.33321/cdi.2025.49.026Keywords:
hepatitis B virus, chronic hepatitis B, mother-to-child transmission, public health, preventative medicine, vaccination, tropical Australia, Aboriginal and Torres Strait Islander peoples, primary healthcareAbstract
Background
With optimal antenatal and perinatal care and immunisation, the risk of perinatal transmission of hepatitis B virus (HBV) approaches zero. However, it can be logistically challenging to deliver this care to culturally and linguistically diverse populations and to those individuals who are living in remote Australian communities. This study examined the management of pregnant women with chronic hepatitis B (CHB) and their children in Far North Queensland (FNQ). It was hoped that this would identify the successes and limitations of the current FNQ HBV programme which was established in June 2017.
Methods
We used the Queensland notifiable diseases register to identify every female of childbearing age (13–45 years) living in FNQ with CHB during the study period 1 January 2013 – 31 December 2023. We identified the children born to these women during the study period and assessed whether their care was concordant with current Australian HBV management guidelines.
Results
We identified 261 women of childbearing age who had 148 live births during the study period: 93/148 children (63%) were born to First Nations Australian mothers; 58/148 (39%) were born to mothers who were born overseas; and 46/148 (31%) were born to mothers who lived in remote locations. After establishment of the FNQ HBV programme, 71/77 pregnancies (92%) had optimal antenatal HBV care; 71/77 (92%) had optimal perinatal HBV care; and 72/77 infants (94%) had complete HBV vaccination. There have been no children confirmed to be hepatitis B surface antigen (HBsAg) positive since the establishment of the FNQ HBV programme. However, only 70/148 children (47%) have had HBsAg testing.
Conclusions
Antenatal and perinatal care and infant vaccination is currently concordant with national HBV guidelines in > 90% of pregnancies in the FNQ region. There has been no confirmed mother-to-child HBV transmission since establishment of a local HBV programme, although improved child testing is necessary to substantiate this finding.
Downloads
References
MacLachlan JH, Romero N, Purcell I, Cowie BC. Viral Hepatitis Mapping Project: Hepatitis B. National Report 2022. Sydney: ASHM; 2024. Available from: https://ashm.org.au/wp-content/uploads/2024/08/Aug-Update2_ASHM_ViralHepReport_2024_HBV-web.pdf.
Hanson J, Fox M, Anderson A, Fox P, Webster K, Williams C et al. Chronic hepatitis B in remote, tropical Australia; successes and challenges. PLoS One. 2020;15(9):e0238719. doi: https://doi.org/10.1371/journal.pone.0238719.
Neldner L, Radlof S, Smith S, Littlejohn M, Hempenstall A, Hanson J. Age of hepatitis B e antigen loss in Aboriginal, Torres Strait Islander and non-Indigenous residents of tropical Australia; implications for clinical care. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.48.
Han C, Karamatic R, Hanson J. Chronic hepatitis B care in regional Australia: implications for clinical practice and public health policy. Intern Med J. 2024. doi: https://doi.org/10.1111/imj.16364.
Riddell J, Hempenstall A, Nakata Y, Gregson S, Hayes R, Smith S et al. The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management. PLoS One. 2023;18(4):e0284151. doi: https://doi.org/10.1371/journal.pone.0284151.
Australian Government Department of Health and Aged Care. 4th National Hepatitis B Strategy 2023–2030. Canberra: Australian Government Department of Health and Aged Care; 2024. Available from: https://www.health.gov.au/sites/default/files/2023-05/fourth-national-hepatitis-b-strategy-2023-2030.pdf.
World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO; 29 March 2024. Available from: https://www.who.int/publications/i/item/9789240090903.
Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B virus transmission. J Pediatric Infect Dis Soc. 2014;3 Suppl 1(Suppl 1):S7–12. doi: https://doi.org/10.1093/jpids/piu064.
Matthews PC, Ocama P, Wang S, El-Sayed M, Turkova A, Ford D et al. Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus. JHEP Rep. 2023;5(8):100777. doi: https://doi.org/10.1016/j.jhepr.2023.100777.
Sheridan J, Donald K, Jameson J. The Queensland hepatitis B program. In Aboriginal Health Information Bulletin no. 12, November 1989, N Thomson, P Merrifield eds. Canberra: Australian Institute of Health and Welfare; 1 November 1989. Available from: https://www.aihw.gov.au/reports/indigenous-australians/aboriginal-health-information-bulletin-no-12-nov/contents/table-of-contents.
Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34. doi: https://doi.org/10.1056/NEJMoa1508660.
Malcolm RL, Ludwick L, Brookes DL, Hanna JN. The investigation of a ‘cluster’ of hepatitis B in teenagers from an indigenous community in North Queensland. Aust N Z J Public Health. 2000;24(4):353–5. doi: https://doi.org/10.1111/j.1467-842x.2000.tb01591.x.
Hanson J, Radlof S, Littlejohn M, Hempenstall A, Edwards R, Nakata Y et al. Hepatitis B genotypes in Aboriginal and Torres Strait Islander Australians: correlation with clinical course and implications for management. Intern Med J. 2024;54(4):647–56. doi: https://doi.org/10.1111/imj.16181.
Lubel JS, Strasser SI, Thompson AJ, Cowie BC, MacLachlan J, Allard NL et al. Australian consensus recommendations for the management of hepatitis B. Med J Aust. 2022;216(9):478–86. doi: https://doi.org/10.5694/mja2.51430.
Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA), Australia. Reference period 2021. [Webpage.] Canberra: Australian Bureau of Statistics; 27 April 2023. Available from: https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-indexes-areas-seifa-australia/2021.
Howell J, Combo T, Binks P, Bragg K, Bukulatjpi S, Campbell K et al. Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action. Med J Aust. 2024. doi: https://doi.org/10.5694/mja2.52395.
Australian Government Productivity Commission. Closing the Gap. Annual Data Compilation Report: July 2024. Canberra: Australian Government Productivity Commission; July 2024. Available from: https://www.pc.gov.au/closing-the-gap-data/annual-data-report/closing-the-gap-annual-data-compilation-july2024.pdf.
Australian Institute of Health and Welfare. The health and welfare of Australia’s Aboriginal and Torres Strait Islander peoples: 2015. Canberra: Australian Institute of Health and Welfare; 9 July 2015. Available from: https://www.aihw.gov.au/reports/indigenous-australians/indigenous-health-welfare-2015/contents/table-of-contents.
Kang K, Chau KWT, Howell E, Anderson M, Smith S, Davis TJ et al. The temporospatial epidemiology of rheumatic heart disease in Far North Queensland, tropical Australia 1997–2017; impact of socioeconomic status on disease burden, severity and access to care. PLoS Negl Trop Dis. 2021;15(1):e0008990. doi: https://doi.org/10.1371/journal.pntd.0008990.
Hanson J, Smith S, Stewart J, Horne P, Ramsamy N. Melioidosis—a disease of socioeconomic disadvantage. PLoS Negl Trop Dis. 2021;15(6):e0009544. doi: https://doi.org/10.1371/journal.pntd.0009544.
Hempenstall A, Howell E, Kang K, Chau KWT, Browne A, Kris E et al. Echocardiographic screening detects a significant burden of rheumatic heart disease in Australian Torres Strait Islander children and missed opportunities for its prevention. Am J Trop Med Hyg. 2021;104(4):1211–4. doi: https://doi.org/10.4269/ajtmh.20-0846.
Coffey PM, Ralph AP, Krause VL. The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: a systematic review. PLoS Negl Trop Dis. 2018;12(6):e0006577. doi: https://doi.org/10.1371/journal.pntd.0006577.
Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework – Summary report March 2024. Canberra: The Australian Institute of Health and Welfare; 2024. Available from: https://www.indigenoushpf.gov.au/.
Dyda A, McGregor S, Binks P, Davies J, Tong SY, Krause V et al. Hepatitis B prevalence in women giving birth in the Northern Territory, Australia, 2005–2015. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.62.
WHO. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. Geneva: WHO; 27 July 2020. Available from: https://www.who.int/publications/i/item/978-92-4-000270-8.
Sullivan RP, Davies J, Binks P, McKinnon M, Dhurrkay RG, Hosking K et al. Preventing early childhood transmission of hepatitis B in remote aboriginal communities in Northern Australia. Int J Equity Health. 2022;21(1):186. doi: https://doi.org/10.1186/s12939-022-01808-z.
Davies J, Smith EL, Littlejohn M, Edwards R, Sozzi V, Jackson K et al. Towards genotype-specific care for chronic hepatitis B: the first 6 years follow up from the CHARM cohort study. Open Forum Infect Dis. 2019;6(11):ofz469. doi: https://doi.org/10.1093/ofid/ofz469.
Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489–92. doi: https://doi.org/10.5694/j.1326-5377.2009.tb02524.x.
Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect. 2013;66(5):447–52. doi: https://doi.org/10.1016/j.jinf.2012.12.008.
Cheah BC, Davies J, Singh GR, Wood N, Jackson K, Littlejohn M et al. Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia. Vaccine. 2018;36(24):3533–40. doi: https://doi.org/10.1016/j.vaccine.2018.01.062.
Hosking K, Binks P, De Santis T, Wilson PM, Gurruwiwi GG, Bukulatjpi SM et al. Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study. Lancet Reg Health West Pac. 2024;48:101116. doi: https://doi.org/10.1016/j.lanwpc.2024.101116.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
